This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmology  • Ophthalmological Disorders  • Dry Eye Syndromes  • Ophthalmological Disorders, Other  • Dermatology  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Immunology  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Julie Gueudry, MD; Michel Binaghi, MD; Marc Muraine, MD, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We appreciate the interest and comments of Sotozono et al regarding our article on the severity and management of ocular complications of SJS and TEN.¹ Both conditions are recognized as 2 of the most devastating ocular surface diseases, and there is no standardized ophthalmologic treatment for the prevention of ocular complications.

Because accumulated clinical and experimental data suggest that the mechanisms of SJS and TEN depend on a medication-specific immune response, corticosteroids and immunosuppressive drugs are used by many physicians. However, these drugs are of unproven benefit at the acute stage, and their use remains highly controversial.^2-3 Furthermore, results of retrospective analyses performed in several burn departments in the United States suggest that the prolonged use of high doses of systemic corticosteroids is associated with increased mortality.⁴ That is why we noted in our discussion¹ that current management . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?